Latest Submitted Abstracts

ISR Autumn Meeting 2017

TBA PRESENTATION (17A120)

Ixekizumab Provides Improvements Through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

ISR Autumn Meeting 2017

TBA PRESENTATION (17A119)

Speed of Onset of Effect on Patient- Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program

ISR Autumn Meeting 2017

TBA PRESENTATION (17A118)

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis: An Integrated Analysis

ISR Autumn Meeting 2017

TBA PRESENTATION (17A117)

Baricitinib Inhibits Radiographic Progression of Structural Joint Damage at 1 Year in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to csDMARDs

ISR Autumn Meeting 2017

TBA PRESENTATION (17A116)

The National Centre For Paediatric Rheumatology (NCPR) Experience of the Use of Tocilizumab (Ro-Actemra) in the treatment of Juvenile Idiopathic Arthritis ( JIA ): A 7-Year Story

ISR Autumn Meeting 2017

TBA PRESENTATION (17A115)

The National Centre For Paediatric Rheumatology (NCPR) Experience of the Use of Tocilizumab (Ro-Actemra) in the treatment of Juvenile Idiopathic Arthritis ( JIA ): A 7-Year Story

ISR Autumn Meeting 2017

TBA PRESENTATION (17A114)

The Rheumatoid Arthritis Susceptibility Gene C5orf30 is an Immunomodulator in Macrophages

ISR Autumn Meeting 2017

TBA PRESENTATION (17A113)

High prevalence of sarcopenia in men with axial spondyloarthropathy

ISR Autumn Meeting 2017

TBA PRESENTATION (17A112)

Obesity predicts worse disease outcomes in axial spondyloarthropathy patients

ISR Autumn Meeting 2017

TBA PRESENTATION (17A111)

“Fast-tracking” a diagnosis of GCA